A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Tirzepatide discontinuation was associated with reduced cardiometabolic benefits especially among patients with body weight regain.

A major 72-week trial shows tirzepatide leads to double-digit weight ... shared decision-making. Further research is needed to determine which therapy best supports long-term weight loss in ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference.

Compared with semaglutide and insulin, tirzepatide was associated with improved ... Disclosure: This research was supported by Eli Lilly and Company. Please see the original reference for a ...

MÁLAGA, Spain — In the first head-to-head trial of its kind, tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity; Eli Lilly) produced significantly greater weight loss ...

those on tirzepatide saw an 18.4 cm (7.2 inches) reduction in waist circumference, compared to 13 cm (5.1 inches) for semaglutide. That difference of more than 2 inches is meaningful. Research ...